Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 25068402 |
US |
55 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 502 | 25068454 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 503 | 25068468 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 504 | 25068520 |
US |
51 | |
Rebound eczema, Incorrect dose administered by device, Therapeutic product effect incomplete, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 505 | 25068528 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 506 | 25068601 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 507 | 25068668 |
US |
5 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, OLOPATADINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 508 | 25068679 |
US |
19 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 509 | 25068707 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, BENRALIZUMAB, |
||||
| 510 | 25068722 |
US |
2 | |
Haematoma, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 511 | 25068729 |
US |
86 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 512 | 25068899 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 513 | 25068911 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 514 | 25068970 |
US |
34 | 2 |
Rash erythematous, Accidental exposure to product, Exposure via skin contact, Device malfunction, |
||||
DUPILUMAB, |
||||
| 515 | 25068999 |
US |
47 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 516 | 25069012 |
US |
73 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 517 | 25069074 |
US |
82 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 518 | 25069167 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 519 | 25069186 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 520 | 25070152 |
US |
60 | 2 |
Exposure via skin contact, Accidental exposure to product, Device use issue, |
||||
MEPOLIZUMAB, |
||||
| 521 | 25070413 |
CA |
59 | 2 |
Accidental exposure to product, Exposure to SARS-CoV-2, Exposure via skin contact, Gastroenteritis listeria, Illness, Immunodeficiency, Intentional dose omission, Pruritus, Rash, Systemic lupus erythematosus, Urinary tract infection, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, FOLIC ACID, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, MONTELUKAST, NAPROXEN, NAPROXEN SODIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 522 | 25070439 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 523 | 25070441 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 524 | 25070443 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 525 | 25070445 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 526 | 25070451 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 527 | 25070460 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 528 | 25070461 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 529 | 25070469 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 530 | 25070473 |
US |
44 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 531 | 25070478 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 532 | 25070487 |
US |
52 | 2 |
Dry skin, Eczema, Injection site pain, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 533 | 25070522 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 534 | 25070568 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 535 | 25070581 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 536 | 25070703 |
US |
71 | 2 |
COVID-19, Illness, Dyspnoea, Condition aggravated, Injury, Accidental exposure to product, Exposure via skin contact, Limb injury, |
||||
DUPILUMAB, |
||||
| 537 | 25070747 |
US |
||
Chest pain, Hypotension, Hypertension, Bradycardia, Electrocardiogram QT prolonged, Electrocardiogram abnormal, Tachycardia, Conduction disorder, Depressed level of consciousness, Rhabdomyolysis, Syncope, Intentional product misuse, Electrolyte imbalance, Blood creatinine increased, Dizziness, Vertigo, Visual impairment, Somnolence, Lethargy, Agitation, Dysarthria, Tremor, Headache, Tinnitus, Muscular weakness, Neurological symptom, Vomiting, Nausea, Diarrhoea, Dyspnoea, Cyanosis, Erythema, Flushing, Hyperhidrosis, Drug ineffective, Adverse drug reaction, Therapeutic product effect incomplete, Accidental exposure to product, Accidental exposure to product by child, Medication error, |
||||
IVABRADINE, |
||||
| 538 | 25070763 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 539 | 25070774 |
US |
66 | 1 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 540 | 25070783 |
US |
22 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 541 | 25070799 |
US |
57 | 2 |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 542 | 25070815 |
US |
43 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, RUXOLITINIB, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 543 | 25070832 |
US |
73 | 2 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 544 | 25070843 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 545 | 25070848 |
US |
64 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 546 | 25070850 |
US |
22 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 547 | 25070852 |
US |
69 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
DUPILUMAB, |
||||
| 548 | 25070854 |
US |
||
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 549 | 25071418 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 550 | 25071427 |
US |
9 | 1 |
Intercepted product storage error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 551 | 25062341 |
US |
55 | 2 |
Accidental exposure to product, Injection site haemorrhage, Wrong technique in device usage process, Product quality issue, Injection site injury, Product administration error, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, GABAPENTIN, HYDROXYZINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, NALOXEGOL OXALATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, VARENICLINE, VARENICLINE TARTRATE, ALBUTEROL SULFATE, |
||||
| 552 | 25062351 |
US |
||
Wrong technique in device usage process, Skin burning sensation, Skin tightness, Eye irritation, Accidental exposure to product, Pain, Osteoporosis, Arthralgia, Bone pain, Oxygen saturation decreased, Product dose omission issue, |
||||
GLYCOPYRROLATE AND FORMOTEROL FUMARATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 553 | 25062502 |
US |
29 | 2 |
Skin burning sensation, Accidental exposure to product, Incorrect dose administered, Device leakage, |
||||
FREMANEZUMAB-VFRM, |
||||
| 554 | 25063669 |
US |
51 | 2 |
Product dose omission issue, Off label use, Accidental exposure to product, Rash, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, BUPROPION HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, FAMOTIDINE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, HYDROXYZINE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, HYOSCYAMINE SULFATE, ERGOCALCIFEROL, IRON, MELATONIN, DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE, |
||||
| 555 | 25063924 |
US |
79 | 1 |
Eye irritation, Accidental exposure to product, |
||||
DICLOFENAC SODIUM, |
||||
| 556 | 25064381 |
US |
2 | |
Device deployment issue, Incorrect dose administered, Injection site discharge, Accidental exposure to product, Off label use, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 557 | 25064434 |
US |
16 | 1 |
Device malfunction, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, BENZOYL PEROXIDE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, |
||||
| 558 | 25064566 |
US |
38 | 2 |
Accidental exposure to product, Device difficult to use, Wrong technique in product usage process, Drug dose omission by device, Anxiety, Maternal exposure during pregnancy, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 559 | 25064783 |
US |
||
Accidental exposure to product, |
||||
DIAZEPAM, |
||||
| 560 | 25064859 |
JP |
||
Nasopharyngeal cancer, Cutaneous symptom, Product quality issue, Accidental exposure to product, |
||||
MINOXIDIL, OIL, |
||||
| 561 | 25065010 |
US |
1 | |
Device occlusion, Accidental exposure to product, Incorrect dose administered by device, |
||||
SECUKINUMAB, |
||||
| 562 | 25065120 |
US |
1 | |
Device issue, Needle issue, Haemorrhage, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 563 | 25065180 |
CN |
||
Device deployment issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 564 | 25065289 |
US |
42 | 1 |
Exposure via skin contact, Incorrect dose administered by device, Accidental exposure to product, Device issue, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 565 | 25065318 |
US |
27 | 2 |
Device malfunction, Needle issue, Device dispensing error, Device leakage, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 566 | 25065394 |
BR |
||
Product dose omission issue, Accidental exposure to product, Device issue, |
||||
GUSELKUMAB, |
||||
| 567 | 25065901 |
US |
2 | |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 568 | 25056252 |
US |
72 | 2 |
Injection site indentation, Injury associated with device, Accidental exposure to product, Device difficult to use, Device use error, Drug dose omission by device, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 569 | 25056355 |
US |
26 | 2 |
Skin irritation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 570 | 25056716 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 571 | 25057446 |
US |
1 | 2 |
Accidental exposure to product, Product administered to patient of inappropriate age, |
||||
IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, |
||||
| 572 | 25057844 |
US |
53 | 2 |
Accidental exposure to product, Injury associated with device, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 573 | 25058188 |
US |
6 | 1 |
Device malfunction, Accidental exposure to product, Eye irritation, |
||||
BECLOMETHASONE DIPROPIONATE HFA, BECLOMETHASONE DIPROPIONATE HFA, |
||||
| 574 | 25058779 |
US |
1 | |
Syringe issue, No adverse event, Accidental exposure to product, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 575 | 25058906 |
CA |
2 | |
Injection site paraesthesia, Injection site swelling, Injection site haemorrhage, Injection site discolouration, Injection site pain, Injury associated with device, Wrong technique in product usage process, Device failure, Accidental exposure to product, |
||||
EPINEPHRINE, |
||||
| 576 | 25059071 |
US |
61 | 2 |
Accidental exposure to product, Device difficult to use, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 577 | 25059119 |
US |
47 | 2 |
Product communication issue, Accidental exposure to product, Device difficult to use, Wrong technique in product usage process, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 578 | 25059160 |
US |
15 | 1 |
Device difficult to use, Device failure, Product reconstitution quality issue, Liquid product physical issue, Device leakage, Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 579 | 25059269 |
US |
69 | 2 |
Accidental exposure to product, Device difficult to use, Visual impairment, Injection site injury, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 580 | 25059525 |
US |
72 | 1 |
Therapeutic response shortened, Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, Device use error, |
||||
ERENUMAB-AOOE, |
||||
| 581 | 25060108 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 582 | 25060132 |
US |
58 | 2 |
Dermatitis, Incorrect dose administered by device, Device operational issue, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 583 | 25060332 |
US |
100 | 2 |
Accidental exposure to product, Exposure via mucosa, |
||||
DUPILUMAB, |
||||
| 584 | 25060333 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 585 | 25060386 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 586 | 25060411 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 587 | 25060638 |
US |
69 | 2 |
Injection site pain, Device difficult to use, Drug dose omission by device, Accidental exposure to product, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 588 | 25061252 |
US |
||
Product use complaint, Accidental exposure to product, Device malfunction, Product dose omission issue, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, |
||||
| 589 | 25055649 |
US |
72 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 590 | 25055720 |
US |
69 | 2 |
Discomfort, Cough, Pruritus, Nasopharyngitis, Condition aggravated, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 591 | 25055774 |
US |
85 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 592 | 25055787 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 593 | 25055788 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 594 | 25055820 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 595 | 25055854 |
US |
63 | 2 |
Incorrect dose administered, Exposure via skin contact, Incorrect dose administered by device, No adverse event, Accidental exposure to product, Underdose, Product dose omission issue, Device malfunction, |
||||
OMALIZUMAB, OMALIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CARBAMAZEPINE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, HYDROCHLOROTHIAZIDE, |
||||
| 596 | 25055863 |
US |
83 | 2 |
Drug eruption, Urinary tract infection, Pyrexia, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 597 | 25055922 |
US |
32 | 2 |
Injection site bruising, Injection site pain, Product preparation error, Product dose omission in error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 598 | 25055930 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 599 | 25055980 |
US |
70 | 2 |
Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 600 | 25055981 |
US |
40 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28